Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AstraZeneca reports mavrilimumab, sifalimumab studies met primary endpoints
AstraZeneca reports mavrilimumab, sifalimumab studies met primary endpoints
AstraZeneca reports mavrilimumab, sifalimumab studies met primary endpoints
Submitted by
admin
on May 12, 2014 - 11:51am
Source:
The Fly on the Wall
News Tags:
mavrilimumab
sifalimumab
AstraZeneca
MedImmune
lupus
autoimmune disease
rheumatoid arthritis
Headline:
AstraZeneca reports mavrilimumab, sifalimumab studies met primary endpoints
Do Not Allow Advertisers to Use My Personal information
